Date:10/27/2011

cturing scale up procedures, and receive regulatory approvals in the time frames anticipated, our ability to manufacture specified quantities of Cinryze utilizing the existing manufacturing process or additional manufacturing procedures;  our ability to develop life cycle management plans for Cinryze, including designing and commencing clinical studies for additional indications, and pursuing regulatory approvals in additional territories; and our ability to conduct additional studies in the timeframes we anticipate and generate positive results with a Cinryze subcutaneous formulation, Cinryze for antibody mediated rejection and delayed graft function, as well as VP20621 for recurrence of C. difficile.

Our actual results may vary depending on a variety of factors, including:

the development of competitive generic versions of oral Vancocin;

our ability to receive regulatory approval for the use of Cinryze for additional indications and formulations and in additional territories in the timeframes we anticipate or at all;

manufacturing, supply or distribution interruptions, including but not limited to our ability to acquire adequate supplies of Vancocin and Cinryze to meet demand for each product;

our ability to increase manufacturing capacity for Cinryze and the timing and results thereof;

our ability to receive necessary regulatory approvals related to manufacturing capacity increases for Cinryze;

the size of the market, future growth potential and market share for Cinryze in the United States, Europe and other territories;

the size of the market, future growth potential and market share for Buccolam in Europe;

the availability of third party payer reimbursement for Cinryze patients;

fluctuations in wholesaler order patterns and inventory levels;

competition from the approval of products which are currently marketed for other indications by other companies or
'/>"/>

SOURCE ViroPharma Incorporated Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related medicine technology :

1. ViroPharma to Release 2011 Third Quarter Financial Results on October 27, 2011
2. ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia
3. ViroPharma Announces Additional Securities Repurchase Program
4. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
5. ViroPharmas Buccolam® (Midazolam, Oromucosal Solution) Granted European Marketing Authorization for Treatment of Acute Seizures
6. ViroPharma to Participate in the Stifel Nicolaus 2011 Healthcare Conference
7. ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union
8. ViroPharmas Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE)
9. ViroPharma to Participate in the Jefferies 2011 Global Healthcare Conference
10. ViroPharma Launches Swell, an Original Documentary Chronicling the Lives of People Living with Hereditary Angioedema
11. ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI)